 ABC7Chicago.com |
Pfizer nabs FDA nod for another targeted cancer drug
FierceBiotech And the approval marks another win on the targeted cancer drug front for Pfizer, which last year nabbed an FDA OK for its non-small cell lung cancer treatment Xalkori for a subset of patients whose tumors express ALK mutations. The approval for Inlyta, … U.S. Food And Drug Administration Approves Pfizer's INLYTA(R) (axitinib) For … |
View full post on lung cancer – Google News
